Podcasts about Novo Nordisk

Fyringen af Novo Nordisk-direktøren Lars Fruergaard lander som en overraskelse og et mysterie for de fleste. Det hele virker pludseligt og planløst. Og mysteriet bliver kun større af, at beslutningen er truffet af en anden Lars - den tidligere Novo-direktør og nuværende formand for Novo Nordsik Fonden, Lars Rebien. Ingen forstår tilsyneladende, hvad Lars Rebien har gang i - hvorfor ville Lars af med Lars? Det spørgsmål vender vi med DR's erhvervsjournalist, Ole Hall. Vært: Simon Stefanski. Program publiceret i DR Lyd d. 22. maj 2025.

This episode covers: Cardiology This Week: A concise summary of recent studies The role of cardiac magnetic resonance in myocardial disease Air pollution and heart disease Statistics Made Easy: Quasi-experimental study designs Host: Rick Grobbee Guests: Carlos Aguiar, Steffen Petersen, Mark Miller Want to watch that episode? Go to: https://esc365.escardio.org/event/1806 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Rick Grobbee, Nicolle Kraenkel and Mark Miller have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Rick Grobbee Guest: Steffen Petersen Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1806?r Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Rick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Blockbuster drugs. Rising profits. Strong sales. And yet, Novo Nordisk, the Danish company behind the GLP-1 drugs Ozempic and Wegovy, made a surprising move last week: It pushed out its CEO. WSJ's Peter Loftus charts the rise of Ozempic and the fall of CEO Lars Jorgensen. Jessica Mendoza hosts.  Further Listening: Trillion Dollar Shot  Why WeightWatchers Wants in on Drugs Like Ozempic   Sign up for WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

We all know the big economic stories of the year: the trade war, the tariffs. But there's another — even bigger? — story that hasn't been getting the same attention: the Ozempicification of our diets, our bodies and our economy. On this week's TLDR, we take a look at the transformation underway. Plus, economic indicators are telling one story about a potential recession; the headlines are telling another. Which one is right? And, why does it feel like everyone's drinking less alcohol? This episode was hosted by Devin Friedman, business reporter Sarah Rieger and former hedgefunder Matthew Karasz, with an appearance by Armine Yanizyan, Atkinson Fellow on the Future of Workers. Follow us on other platforms, or subscribe to our weekly newsletter: linkin.bio/tldrThe TLDR Podcast is offered by Wealthsimple Media Inc. and is for informational purposes only. The content in the TLDR Podcast is not investment advice, a recommendation to buy or sell assets or securities, and does not represent the views of Wealthsimple Financial Corp or any of its other subsidiaries or affiliates. Wealthsimple Media Inc. does not endorse any third-party views referenced in this content. More information at wealthsimple.com/tldr.

Kara and Scott discuss former President Joe Biden's cancer diagnosis, and the reactions across the political spectrum. Then, Moody's downgrades the U.S. credit rating, and Republicans try to pass Trump's "Big Beautiful Bill." Plus, Walmart and Apple face Trump's bully tactics, Meta delays its new AI model, and Novo Nordisk's CEO is out amid rising competition in the weight loss drug market. Follow us on Instagram and Threads at @pivotpodcastofficial. Follow us on Bluesky at @pivotpod.bsky.social. Follow us on TikTok at @pivotpodcast. Send us your questions by calling us at 855-51-PIVOT, or at nymag.com/pivot. Learn more about your ad choices. Visit podcastchoices.com/adchoices

The turbulence that has come with the Trump administration's policies related to the U.S. biopharmaceutical industry is creating an opening for Europe to bolster its life sciences industry. On the latest BioCentury This Week podcast, BioCentury's editors look at how Europe can capitalize on staffing cuts at FDA and NIH and an uncertain policy environment to lure back talent to bolster regulatory agencies and biotech R&D engines and attract assets and partners from China.The editors also discuss two biotech deals driven by former leaders of BD at Roche, Biomarin's James Sabry and Sophie Kornowski at Boston Pharmaceuticals. Under the leadership of Sabry and CEO Alexander Hardy, Biomarin delivered its first takeout in a decade by acquiring Inozyme as it positions itself to take advantage of a regulatory and policy environment that they believe is favorable to their rare disease strategy. CEO Kornowski, meanwhile, executed on a plan to focus her company on a single liver disease asset that GSK acquired for $1.2 billion up front. Finally, BioCentury's editors discuss the management shake-up at obesity company Novo Nordisk, where Lars Fruergaard Jørgensen, the leader who spearheaded Novo Nordisk's transformation into a dominant player in obesity, is stepping down.Chan Zuckerberg Chicago Biohub is hosting an exclusive, invite-only reception on June 3 — the eve of BioCentury's Grand Rounds conference — gathering top voices in biotech innovation and investment to exchange bold ideas, spark new collaborations and channel the energy of Chicago's thriving innovation ecosystem. If you're interested in attending, please register here. This episode was sponsored by Jeito Capital.View full story: https://www.biocentury.com/article/655964#biotech #biopharma #pharma #lifescience #politics #policy #law00:01 - Sponsor Message: Jeito Capital05:05 - European Biotech's Moment?19:00 - Boston Pharma, Biomarin Deals29:41 - Novo Nordisk CEOTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Rafal Trzaskowski, the liberal mayor expected to win the first round cleanly only squeaked by. We ask what's at stake in the NATO-front-line country now the second round looks so uncertain. In the new world of weight-loss drugs Wegovy, from Novo Nordisk, has reigned supreme—perhaps not for much longer (9:40). And people really do look—but also act—like their dogs (16:51).Get a world of insights by subscribing to Economist Podcasts+. For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account. Hosted on Acast. See acast.com/privacy for more information.

Rafal Trzaskowski, the liberal mayor expected to win the first round cleanly only squeaked by. We ask what's at stake in the NATO-front-line country now the second round looks so uncertain. In the new world of weight-loss drugs Wegovy, from Novo Nordisk, has reigned supreme—perhaps not for much longer (9:40). And people really do look—but also act—like their dogs (16:51).Get a world of insights by subscribing to Economist Podcasts+. For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account.

Join experts in obesity, Dr Robert Kushner, Dr Aaron Kelly, and Dr Edmond “Trey” Wickham, as they discuss the difficulties of navigating the terrain of adolescent obesity. • Robert Kushner, MD • Aaron Kelly, PhD • Edmond “Trey” Wickham, MD This podcast is sponsored by Novo Nordisk and is intended for healthcare professionals.

當你忙到沒時間吃飯、又不想亂吃，來一杯好喝又營養的 Benefit Body 蛋白飲剛剛好。 植物配方低負擔、取代手搖也沒問題!

USA's finansminister Scott Bessent advarer lande, der endnu ikke har indgået en handelsaftale med USA. Fyringen kom også som en overraskelse for Novo Nordisk-topchefen. De to parter, Ukraine og Rusland, er ikke kommet tættere på at afvikle krigen. Israel har påbegyndt omfattende landope­ra­tioner i Gaza. Vindpro­jekt bliver pludselig aflyst efter 13 år.   Vært: Trine Duvander (trdu@borsen.dk)

In this insightful Market Mondays clip, Rashad Bilal, Ian Dunlap, and Troy Millings break down two of the week's biggest financial headlines that could shake up the markets: President Trump's executive order to lower prescription drug prices and Amazon's strategic acquisition of AMD shares. First, the hosts dive deep into the possible long-term impacts of Trump's new executive order aiming to slash prescription drug costs across the board. They discuss the potential winners—everyday consumers in need of lower medication costs—and the possible losers, notably major pharmaceutical companies that may see profit margins squeezed. The conversation covers how this move could spur much-needed innovation within the healthcare sector, but also draws attention to challenges such as lobbying pressure and lengthy litigation. What does this mean for healthcare stocks like Pfizer, Eli Lilly, Novo Nordisk, Johnson & Johnson, CVS, Amgen, and more? The hosts lay out possible outcomes and the bigger economic picture, including references to Mark Cuban's earlier ideas about drug pricing and fair access.Next up, the crew unpacks the real story behind Amazon's much-discussed “purchase” of $84 million in AMD shares. Is this a direct investment or the result of AMD's acquisition of ZT Group International—where Amazon already had stakes? They clarify the technical details and examine how this plays into Amazon's push for self-reliance in AI infrastructure and chip development, following in the footsteps of giants like Apple making their own chips. The discussion also touches on how this integration of hardware and internal resources could position Amazon for even more dominance in the AI race and tech industry at large.Throughout the clip, Rashad, Ian, and Troy provide honest takes on market strategies, investment insights, and the political chess game playing out in real time. From healthcare innovation to tech self-sufficiency, this conversation is a must-watch for investors, entrepreneurs, and anyone wanting to stay ahead of the curve on Wall Street.Don't forget to like, comment, and subscribe for more in-depth market analysis and actionable insights!#MarketMoves #PrescriptionDrugs #HealthcareStocks #TrumpNews #Amazon #AMD #TechStocks #AI #Investing #StockMarket #Finance #BusinessNews #MarkCuban #Pharma #EliLilly #Pfizer #JohnsonAndJohnson #Pharmaceuticals #Innovation #BusinessAnalysis #AmazonPrime #WallStreet #FinancialNewsSupport this podcast at — https://redcircle.com/marketmondays/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Join this multidisciplinary discussion with Joseph Arulandu, MD, FACP, Michael Blaha, MD and Melissa Magwire RN, MSN, as they discuss the interconnected nature and the significant co-existence of cardiometabolic diseases. Joseph R. Arulandu, MD, FACP Michael J. Blaha, MD, MPH Melissa Magwire, RN, MSN, CDCES This podcast is sponsored by Novo Nordisk and is intended for healthcare professionals.

The credit rating agency Moody's has stripped the United States of its triple-A credit rating, warning investors about rising levels of government debt and a widening budget deficit. The agency has shifted the US rating down one notch to AA1, while changing its outlook from negative to stable. Novo Nordisk, the company that makes the weight loss drugs Ozempic and Wegovy, is abruptly ousting its chief executive, Lars Fruergaard Jørgensen, over concerns the firm is losing ground in the popular weight-loss drug market. Consumer boycotts of countries and companies are on the rise, with the latest being an Indian tourism boycott of Turkey and Azerbaijan. This comes as some Canadians boycott the US, while others refuse to buy from some specific companies over their policies. We will be joined throughout the programme by Rahul Tandon is joined by two guests on opposite sides of the world: Lori Ann Larocco, senior editor at CNBC Business News in the US, and Peter Ryan, ABC's senior business correspondent in Australia.

Carl Quintanilla, Jim Cramer and David Faber kicked off the hour by discussing the S&P aiming for its 5th straight day of gains, with megacap tech stocks leading the charge. Nvidia and Tesla shares were up double digits since Monday. Faber also broke down the deal of the day, as Charter announced it would acquire Cox Communications to create one of the largest cable companies in the U.S. Also in the mix: Novo Nordisk announced that CEO Lars Jorgensen would be stepping down from his role, citing recent market challenges. Shares of Novo Nordisk were down more than 50% over the last full-year of trading.  Squawk on the Street Disclaimer 

Novo Nordisk, the company that makes the weight loss drugs Ozempic and Wegovy, is abruptly ousting its chief executive, Lars Fruergaard Jørgensen, over concerns the firm is losing ground in the popular weight-loss drug market. Consumer boycotts of countries and companies are on the rise, with the latest being an Indian tourism boycott of Turkey and Azerbaijan. This comes as some Canadians boycott the US, while others refuse to buy from some specific companies over their policies. And Rahul Tandon hears about why some private companies in the USA see an opportunity in this rail sector, as there are concerns over the US federal government looking to pull back from supporting rail.

Ben and Tom discuss the potential Charter and Cox Communications merger, Meta's AI delays, and Novo Nordisk firing its CEO. For information on how to join the Zoom calls live each morning at 8:30 EST, visit:https://www.narwhal.com/blog/daily-market-briefingsPlease see disclosures:https://www.narwhal.com/disclosure

Stock market update for May 16, 2025.

Mark Zuckerberg zal geen fijne dag hebben. Die wordt namelijk ingehaald door zijn grote concurrent, TikTok. Moederbedrijf Bytedance ziet de omzet met 20 procent stijgen, ondanks de pogingen van de VS om TikTok op zwart te zetten. Daardoor zou Bytedance eind dit jaar even groot zijn als Zuckerberg's Meta. Christine Lagarde schreef al drie keer geschiedenis: als eerste vrouwelijke financiënminister in Frankrijk, als eerste vrouw die het IMF leidde, en als eerste vrouwelijke baas van de Europese Centrale Bank. Maar daar kan een vierde bladzijde bijkomen. Volgens Bloomberg maakt ze namelijk ook goede kans op het stoeltje van Klaus Schwab bij het World Economic Forum. Gaat ze daarvoor vervroegd vertrekken bij de ECB? Verder gaat het over Novo Nordisk. Beleggers zijn in de war, want de topman vertrekt opeens. Vermoedelijke reden: de farmaceut verliest de competitie om afvalmedicatie van concurrent Eli Lilly. En dat raakt de prijs van het aandeel te hard. Maar de vraag blijft of het wegsturen van de ceo dat gaat oplossen. Je hoort ook wat er aan de hand is bij Coinbase. Het cryptoplatform krijgt twee klappen te verwerken. Iemand perst ze af, maar de toezichthouder denkt ook dat Coinbase zelf beleggers uitperst. En we blikken terug op de week van Donald Trump. Zijn regering sloot plotseling een tijdelijke deal met China. En zelf zat hij ook niet stil, want hij wist honderden miljarden dollars los te peuteren in het Midden Oosten.See omnystudio.com/listener for privacy information.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.At a recent U.S. Senate hearing, Health and Human Services Secretary was questioned about cuts being made to the department and his stance on endorsing the measles vaccine during a growing outbreak. The hearing was tense at times, with RFK Jr. firm on supporting the cuts but wavering on his stance on the MMR vaccine. AbbVie's ADC received accelerated approval for lung cancer treatment, FDA delays decision on Biohaven's application, and chaos ensues at the FDA's advisory committee planning office after workforce cuts. Sino Biological offers solutions for autoimmune disease research, with reagents for nearly 50 diseases. Novo Nordisk has invested $2.4 billion in a new oral obesity drug through a deal with Septerna, aiming to catch up with competitors in the oral weight loss space. AbbVie has committed $335 million upfront in a partnership with Adarx Pharmaceuticals for siRNA research, while GSK has abandoned a TIGIT therapy and instead acquired rights to a liver drug from Boston Pharmaceuticals for potential $2 billion deal. This news highlights the ongoing developments and investments in the pharmaceutical industry.

Howie and Harlan are joined by James Dodington, a Yale pediatric emergency medicine physician and an expert in community-based violence prevention. Harlan reports on the remarkable financial results and sometimes questionable science of Hims & Hers Health; Howie discusses UnitedHealthcare's faltering stock price in the face of anger over aggressive care denial and a lawsuit from shareholders. Links: Oscar Health and Hims & Hers “Oscar Health Profits Eclipse $275 Million As Obamacare Enrollment Soars” “Hims & Hers Health Revenue Jumps, But Outlook Disappoints” “Hims & Hers' Q1 revenue doubles to $586M, boosted by growth in weight loss business” “Novo Nordisk to sell Wegovy through telehealth firms to cash-paying US customers” “They Wanted a Quick Fix for Hair Loss. Instead, These Young Men Got Sick.” “EU drugs regulator confirms suicidal thoughts as side effect of hair loss drug” “Measures to minimise risk of suicidal thoughts with finasteride and dutasteride medicines” “FDA alerts health care providers, compounders and consumers of potential risks associated with compounded topical finasteride products” James Dodington Health & Veritas Episode 81: Joseph Sakran: Confronting Gun Violence Health & Veritas Episode 77: Megan Ranney: What's Next for Public Health? “Children and teens are more likely to die by guns than anything else” “U.S. Surgeon General Issues Advisory on the Public Health Crisis of Firearm Violence in the United States” “New Report Highlights U.S. 2022 Gun-Related Deaths: Firearms Remain Leading Cause of Death for Children and Teens, and Disproportionately Affect People of Color” James Dodington: “Rural Versus Urban Hospitalizations for Firearm Injuries in Children and Adolescents” “Disparities in Pediatric Mental and Behavioral Health Conditions” “Special Report: Dean Megan Ranney Brings a Public Health Approach to the Country's Gun Violence Epidemic” “Gun Violence Is a Public Health Crisis—But Hospital-based Intervention Programs Can Help Break the Cycle” “Implementation of an emerging hospital-based violence intervention program: a multimethod study” UCSF Wraparound Project: The Public Health Model for Violence Prevention “Just Listen” Firearm Injury Prevention at the Yale School of Public Health “11 Years After Sandy Hook—A New Path Toward Healing and Hope” Nelba Márquez-Greene's Shared Humanity Podcast 4-CT:Violence Intervention and Prevention “Cash Pilot Targets Violence Victims” “How unrestricted cash aid is transforming violence intervention in Connecticut” “Yale undergraduate team takes first place in national health policy competition” UnitedHealthcare “UnitedHealth CEO Is Out, Sending Shares Plummeting” “UnitedHealthcare sued by shareholders over reaction to CEO's killing” UnitedHealth Shareholder Lawsuit “UnitedHealth's string of setbacks, from exec murder to cyber attack” “Zepbound Patients Fear Losing Coverage After CVS Deal for Wegovy” “Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs”  

President Donald Trump unveiled a sweeping drug pricing policy this week, seeking to lower drug prices in the U.S. by up to 80% through a reprisal of the Most Favored Nation rule he attempted to introduce in his first term. The rule would essentially link U.S. prices to those paid in other nations where medications are cheaper. Biopharma reaction was one of tentative relief, with BMO Capital Markets analysts suggesting the executive order had “more bark than bite.” Meanwhile, the Centers for Medicare and Medicaid Services announced that among the next 15 drugs to undergo IRA-prescripted price negotiations could be drugs payable through Medicare Part B, and not just Part D, where the first two rounds have applied.  Into all of this action steps Vinay Prasad, the outspoken oncologist and hematologist who was named last week as the next director of the FDA's Center for Biologics Evaluation and Research. While the S&P Biotech ETF fell by more than 5% upon the news, overall reaction was fairly measured, with cell and gene therapy executive Audrey Greenberg summing up Prasad's selection as “anything but a status quo appointment.”  Over in the weight loss and obesity space, Eli Lilly can't seem to lose. This weekend, Lilly announced full data from a head-to-head trial showing a “superior benefit-to-risk ratio” for its Zepbound over Novo Nordisk's Wegovy. And last week, the Indiana-based pharma won a court battle against compounders when a judge sided with the FDA, stating that tirzepatide—the active ingredient in both Zepbound and diabetes sister drug Mounjaro—was no longer in shortage. Add on a presidential shoutout during Trump's Monday press conference for its U.S. manufacturing investments, and it really was Lilly's week.  Flying less high are some 2,000 Bayer employees who lost their jobs in the first quarter of 2025 as part of the company's new operating model, which is intended to make Bayer “much more agile.” On a less direct flight is Galapagos, which reversed course on plans to spin out a portion of the company and find a new CEO. Instead, CEO Paul Stoffels will make a quicker exit and the Belgian biotech could sell off its cell therapy assets as it looks to build up a new pipeline in house, having abandoned the spinout idea altogether. Stay tuned.  Finally, in ClinicaSpace this week, we took a deep dive into the HIV treatment space, where companies like Gilead and Immunocore are targeting a cure, while the Trump administration slashes funding for HIV research.  

Afslankmedicijnen vliegen als warme broodjes over de toonbank. In een farmaceutische afvalrace strijden Eli Lilly en Novo Nordisk om het beste medicijn. Sinds kort lijkt Eli Lilly de beste kaarten in handen te hebben. In hoeverre helpen die medicijnen nou echt overgewicht de wereld uit? En hoe afhankelijk is het bedrijf inmiddels geworden van het afslankmiddel Mounjaro? Marco Frenken, country manager van Eli Lilly Nederland is te gast in BNR Zakendoen. Macro met Mujagić/Boot Elke dag een intrigerende gedachtewisseling over de stand van de macro-economie. Op maandag en vrijdag gaat presentator Thomas van Zijl in gesprek met econoom Arnoud Boot, de rest van de week praat Van Zijl met econoom Edin Mujagić. Ook altijd terug te vinden als je een aflevering gemist hebt. Blik op de wereld Wat speelt zich vandaag af op het wereldtoneel? Het laatste nieuws uit bijvoorbeeld Oekraïne, het Midden-Oosten, de Verenigde Staten of Brussel hoor je iedere werkdag om 12.10 van onze vaste experts en eigen redacteuren en verslaggevers. Ook los te vinden als podcast. Lobbypanel Culturele organisaties moeten langer subsidie krijgen. En kan de premie verplichte verzekering voor zelfstandigen tegen arbeidsongeschiktheid omlaag? Dat en meer bespreken we in het lobbypanel met: - Nora van Elferen, partner bij EPPA - Debbie de Wagenaar, reputatiemanager voor bedrijven Luister l Lobbypanel | Zakenlunch Elke dag, tijdens de lunch, geniet je mee van het laatste zakelijke nieuws, actuele informatie over de financiële markten en ander economische actualiteiten. Op een ontspannen manier word je als luisteraar bijgepraat over alles wat er speelt in de wereld van het bedrijfsleven en de beurs. En altijd terug te vinden als podcast, mocht je de lunch gemist hebben. Contact & Abonneren BNR Zakendoen zendt elke werkdag live uit van 11:00 tot 13:30 uur. Je kunt de redactie bereiken via e-mail. Abonneren op de podcast van BNR Zakendoen kan via bnr.nl/zakendoen, of via Apple Podcast en Spotify. See omnystudio.com/listener for privacy information.

Nu er der landet en toldaftale mellem Kina og USA. Donald Trump langer ud efter medicinalindustrien og Novo Nordisk. Inflation i Danmark. Pengene er væltet ind i statskassen. Mulige forhandlinger om våbenhvile mellem Rusland og Ukraine. Afgiftssmæk på elbiler. Trumps besøg i Saudi Arabien.   Vært: Trine Duvander (trdu@borsen.dk)

What is the risk of developing cardiovascular disease if you have obesity? Join experts in obesity, Dr. Robert Kushner and Dr. Michael Blaha, as they discuss the elevated cardiovascular risk associated with obesity and overweight. Speakers: • Bob Kushner, MD • Michael Blaha, MD, MPH This podcast is sponsored by Novo Nordisk and is intended for clinicians.  

In this episode, we dive into Warren Buffett's succession and legacy, the philosophy that built Berkshire Hathaway, and what the future might hold under Greg Abel. We also break down recent dividend news, from Apple's modest hike to Wendy's surprising cut, and share our own May dividend income.We cover earnings from some major names like Novo Nordisk, Archer Daniels Midland, Ahold Delhaize, and Legrand, plus explore the intriguing possibility of Shell acquiring BP. Listener questions spark some great discussion, including what football clubs would be as dividend stocks, whether our podcast can move markets, and which companies have the strongest moats.

The Friday Five for May 9, 2025: Rite Aid Files for Chapter 11 Bankruptcy Again Apple WWDC 2025 Dates & Rumors Discount Medicare Insurance Scam Alert Rueppel Recommends Books & Streaming Picks May 2025 Aetna Health Plans to Exit ACA Marketplace for CY 2026   Rite Aid Files for 2nd Chapter 11 Bankruptcy: Download the “Rite Aid Letter to Customers - May 5, 2025.” Restructuring.Ra.Kroll.Com, Kroll Restructuring Administration, restructuring.ra.kroll.com/RiteAid/Home-DownloadPDF?id1=MzM0MTA2Mg%3D%3D&id2=0. Accessed 6 May 2025. Grothaus, Michael. “Rite Aid Bankruptcy: What to Know about Store Closings, Prescription Transfers, Layoffs, Gift Cards, and More.” Fastcompany.Com, Fast Company, 6 May 2025, www.fastcompany.com/91329223/rite-aid-bankruptcy-2025-stores-closing-prescription-transfers-gift-cards. Arias, Pilar. “Rite Aid Files for Bankruptcy for Second Time in Less than 2 Years.” Foxbusiness.Com, Fox Business, 6 May 2025, www.foxbusiness.com/economy/rite-aid-files-bankruptcy-second-time-less-than-2-years. Powel, James. “Rite Aid Files for Chapter 11 Bankruptcy, Promises ‘smooth Transfer' of Prescriptions.” Usatoday.Com, Gannett Satellite Information Network, 6 May 2025, www.usatoday.com/story/money/retail/2025/05/05/rite-aid-chapter-11-bankruptcy/83467189007/. “Rite Aid Store Locater.” Riteaid.Com, Rite Aid, www.riteaid.com/locations/. Accessed 6 May 2025. Urie, Daniel. “Rite Aid Tells Vendors It ‘Has Generally Stopped Purchasing Goods and Services.'” Pennlive.Com, PennLive, 5 May 2025, www.pennlive.com/business/2025/05/rite-aid-tells-vendors-it-has-generally-stopped-purchasing-goods-and-services.html. Mills, Sean I. “What to Do with Your Prescriptions Now That Rite Aid Is Closing All Stores.” Romesentinel.Com, Daily Sentinel, 6 May 2025, www.romesentinel.com/news/rome-new-hartford-rite-aid-store-closings/article_98f2300b-600c-4937-b8d0-686ece8d36e9.html.   Apple WWDC 2025 Dates & Rumors: Lovejoy, Ben. “90% of People Shouldn't Buy the iPhone 17 Air, per Apple.” 9to5mac.Com, 9to5Mac, 6 May 2025, 9to5mac.com/2025/05/06/90-of-people-shouldnt-buy-the-iphone-17-air-per-apple/. Schroeder, Stan. “Apple Is Planning a New iPhone Launch Schedule, Report Claims.” Mashable, Mashable, 5 May 2025, mashable.com/article/apple-iphone-launch-schedule. “iOS 7 vs iOS 6 Side-by-Side Visual Comparisons.” Osxdaily.Com, OS X Daily, osxdaily.com/2013/06/11/ios-7-vs-ios-6-visual-comparison/. Accessed 6 May 2025. Christoffel, Ryan. “iOS 19: Three New Features Are Being Announced next Month.” 9to5mac.Com, 9to5Mac, 5 May 2025, 9to5mac.com/2025/05/05/ios-19-three-new-features-are-being-announced-next-month/. Clover, Juli. “iOS 19: Everything We Know.” Macrumors.Com, MacRumors, 5 May 2025, www.macrumors.com/roundup/ios-19/.   Discount Medicare Insurance Scam Alert: “Emerging Discount Medical Insurance Scams.” Ic3.Gov, Internet Crime Complaint Center (IC3), 30 Apr. 2025, www.ic3.gov/PSA/2025/PSA250430. Dimuro, Claudia. “FBI Alerts Public in Pa., beyond to Emerging Scam: Here's What to Know.” Pennlive.Com, PennLive, 5 May 2025, www.pennlive.com/life/2025/05/fbi-alerts-public-in-pa-beyond-to-emerging-scam-heres-what-to-know.html. Burman, Theo. “FBI Issues New Warning Over Health Insurance Scams.” Newsweek.Com, Newsweek, 6 May 2025, www.newsweek.com/fbi-issues-new-warning-over-health-insurance-scams-2068626.   Rueppel Recommends: Wynn-Williams, Sarah. “Careless People: A Cautionary Tale of Power, Greed, and Lost Idealism.” Spotify, Flatiron Books, open.spotify.com/show/279JRLPYDjvmsS81C7SOzg?si=215e5504c3ea4510. Accessed 6 May 2025. Ridgely, Charlie. “Everything Coming to Netflix, Max, Disney+ & Other Streaming Services in May 2025.” ComicBook.Com, ComicBook, 30 Apr. 2025, comicbook.com/tv-shows/news/new-streaming-movies-tv-shows-may-2025-netflix-disney-max/. Bet-David, Patrick. “Your Next Five Moves: Master the Art of Business Strategy.” Spotify, Gallery Books, https://open.spotify.com/show/1mCTkhoZxUOH6iA9b8Dx2y?si=b11263c88e3a43ff. Accessed 6 May 2025. Bet-David, Patrick. Your Next Five Moves, Gallery Books, www.yournextfivemoves.com/. Accessed 6 May 2025.   Aetna Health Plans to Exit ACA Marketplace for CY 2026: Minemyer, Paige. “Aetna to Exit the ACA Exchanges in 2026.” Fiercehealthcare.Com, Fierce Healthcare, 1 May 2025, www.fiercehealthcare.com/payers/aetna-exit-aca-exchanges-2026. Pifer, Rebecca. “CVS Plans to Exit ACA Individual Exchanges, Strikes Wegovy Deal with Novo Nordisk.” Healthcaredive.Com, Healthcare Dive, 1 May 2025, www.healthcaredive.com/news/cvs-aetna-exit-aca-novo-nordisk-wegovy-deal/746833/. Japsen, Bruce. “CVS Plans To Exit Obamacare In 2026, Affecting 1 Million Aetna Members.” Forbes.Com, Forbes Magazine, 1 May 2025, www.forbes.com/sites/brucejapsen/2025/05/01/cvs-plans-to-exit-obamacare-in-2026-impacting-1-million-aetna-members/. How Plan Crosswalks Work in the ACA Marketplace: https://lnk.to/ASG664   Resources: 5 Myths About Selling ACA Health Insurance Plans: https://lnk.to/asg660  5 Things from the CMS 2026 MA and Part D Final Rule: https://lnk.to/asgf20250502  Agent Requirements for ACA Sales: https://lnk.to/ASG662 Learn How to Sell ACA Products During the Off-Season ft. Danica Stover: https://lnk.to/asg661  Leveling Up: From Chill Mode to Growth Mode ft. Christian Brindle: https://lnk.to/brindle2025   Follow Us on Social!  Ritter on Facebook, https://www.facebook.com/RitterIM Instagram, https://www.instagram.com/ritter.insurance.marketing/ LinkedIn, https://www.linkedin.com/company/ritter-insurance-marketing TikTok, https://www.tiktok.com/@ritterim X, https://x.com/RitterIM and YouTube, https://www.youtube.com/user/RitterInsurance     Sarah on LinkedIn, https://www.linkedin.com/in/sjrueppel/ Instagram, https://www.instagram.com/thesarahjrueppel/ and Threads, https://www.threads.net/@thesarahjrueppel  Tina on LinkedIn, https://www.linkedin.com/in/tina-lamoreux-6384b7199/   Not affiliated with or endorsed by Medicare or any government agency. Contact the Agent Survival Guide Podcast! Email us ASGPodcast@Ritterim.com or call 1-717-562-7211 and leave a voicemail.

Howie and Harlan are joined by Thomas Gill, a Yale geriatrician whose research tracks the factors that contribute to disability in older adults—and those that support continued independence. And they discuss the contrarian tapped to evaluate vaccines at the FDA, allegations of kickbacks against insurers, and the potential end of a loophole that has allowed states to collect additional Medicaid funding.  Links: Vinay Prasad at the FDA “Vinay Prasad tapped to run FDA center that regulates vaccines, gene therapies” “Vinay Prasad, in his own words, outlines the philosophy he'll bring to the FDA” “Peter Marks, FDA's top vaccine regulator, forced out” Howard Forman on LinkedIn on Vinay Prasad's Appointment Vinay Prasad's Substack Insurance News “Justice Department Sues Big Medicare Insurers Alleging Kickbacks” “Aetna to exit the ACA exchanges in 2026” “What Aetna quitting the exchanges says about the exchanges” ”CVS to boost access to Novo Nordisk's weight loss treatment Wegovy for patients on its drug plans” Thomas Gill Statista: Share of old age population (65 years and older) in the total U.S. population from 1950 to 2050 Thomas Gill: “A physical activity intervention to treat the frailty syndrome in older persons-results from the LIFE-P study” Thomas Gill: “A Program to Prevent Functional Decline in Physically Frail, Elderly Persons Who Live at Home” “Prehabilitation for Patients Undergoing Orthopedic Surgery: A Systematic Review and Meta-analysis” “Allostatic Load: Importance, Markers, and Score Determination in Minority and Disparity Populations” “Cohort Profile: The Precipitating Events Project (PEP Study)” “In Memoriam: Yale Expert in Clinical Research Methods, Alvan R. Feinstein” Medicaid Cuts “Putting $880 Billion in Potential Federal Medicaid Cuts in Context of State Budgets and Coverage” “Republicans are running out of ways to cut Medicaid as moderates and hard-liners clash” “G.O.P. Targets a Medicaid Loophole Used by 49 States to Grab Federal Money” Learn more about the MBA for Executives program at Yale SOM. Email Howie and Harlan comments or questions.

En este episodio cubrimos lo más relevante antes de la apertura de Wall Street: • Wall Street se anima por reunión EE.UU.–China: Futuros al alza: $SPX, $US100 y $INDU +0.6%. La expectativa de avances comerciales se suma a la espera por la decisión de tasas de la Fed. Se anticipa que el FOMC mantenga tasas sin cambios, pero el foco está en las palabras de Jerome Powell tras la presión pública de Trump por recortes. • Cisco impulsa su apuesta cuántica: $CSCO presentó su chip Quantum Network Entanglement y abrirá un laboratorio en California. Tecnología de baja energía, operativa a temperatura ambiente y con hasta 200M pares de entrelazamiento por segundo. Se suma a la carrera cuántica junto a $GOOG, $MSFT, $AMZN y $NVDA. • CoreWeave fortalece su músculo financiero: $CRWV eleva su línea de crédito de $650M a $1.5B con bancos como JPMorgan y Goldman Sachs. Busca expandir infraestructura de nube enfocada en IA. Pese a tensiones pasadas por deuda, las entidades muestran confianza en su crecimiento futuro. • Novo Nordisk ajusta guía, pero sube: $NVO reportó ingresos por $11.9B (+19% YoY) en Q1 2025, aunque ventas de Wegovy decepcionaron. Aun así, la acción sube al anticipar recuperación en ventas tras el cierre de vacíos regulatorios en EE.UU. Nueva guía: +13%-21% en ventas para el año. Un episodio cargado de noticias clave antes de que arranque el mercado. ¡No te lo pierdas!

In der heutigen Folge von „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Daniel Eckert über die Magie der Mausaktie Disney, Insolvenz einer Diät-Ikone und den stoischen Kurs der Fed. Außerdem geht es um Alphabet, Nvidia, Uber, Charles River Laboratories, Hensoldt, Fresenius, Vonovia, Carl Zeiss Meditec, Eli Lilly, Novo Nordisk, WeightWatchers, Volkswagen, Mercedes, BMW, Ferrari, Nvidia, Meta Platforms, Microsoft, Altria, Saudi-Aramco, AppLovin, ConocoPhillips, CNOOC, Investor AB, Arista Networks, Visa, Blackstone, KKR, Pinduoduo, Investor AB, Hermès, Münchener Rück, Allianz, Deutsche Telekom, SAP, MicroStrategy und Vertex Pharmaceuticals. Wir freuen uns an Feedback über aaa@welt.de. Ab sofort gibt es noch mehr "Alles auf Aktien" bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

This episode covers: Cardiology This Week: A concise summary of recent studies Colchicine for secondary prevention An algorithmic approach to the workup of syncope Milestones: CIBIS II Host: Rick Grobbee Guests: Carlos Aguiar, Sanjit Jolly, Michele Brignole Want to watch that episode? Go to: https://esc365.escardio.org/event/1805 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Michele Brignole, Diederick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Sanjit Jolly has declared to have potential conflicts of interest to report: grant support from Boston Scientific, honorarium from Boston Scientific, Shockwave, Abiomed, SIS, and Teleflex.  Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Rick Grobbee Guest: Michele Brignole Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1805?r  Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Michele Brignole, Diederick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

En este episodio cubrimos lo más relevante antes de la apertura de Wall Street: • Wall Street se anima por reunión EE.UU.–China: Futuros al alza: $SPX, $US100 y $INDU +0.6%. La expectativa de avances comerciales se suma a la espera por la decisión de tasas de la Fed. Se anticipa que el FOMC mantenga tasas sin cambios, pero el foco está en las palabras de Jerome Powell tras la presión pública de Trump por recortes. • Cisco impulsa su apuesta cuántica: $CSCO presentó su chip Quantum Network Entanglement y abrirá un laboratorio en California. Tecnología de baja energía, operativa a temperatura ambiente y con hasta 200M pares de entrelazamiento por segundo. Se suma a la carrera cuántica junto a $GOOG, $MSFT, $AMZN y $NVDA. • CoreWeave fortalece su músculo financiero: $CRWV eleva su línea de crédito de $650M a $1.5B con bancos como JPMorgan y Goldman Sachs. Busca expandir infraestructura de nube enfocada en IA. Pese a tensiones pasadas por deuda, las entidades muestran confianza en su crecimiento futuro. • Novo Nordisk ajusta guía, pero sube: $NVO reportó ingresos por $11.9B (+19% YoY) en Q1 2025, aunque ventas de Wegovy decepcionaron. Aun así, la acción sube al anticipar recuperación en ventas tras el cierre de vacíos regulatorios en EE.UU. Nueva guía: +13%–21% en ventas para el año. ¡Dale play y entérate de todo lo que mueve el mercado hoy!

Det vælter ind med interessante regnskaber fra de store danske aktieselskaber. Millionærklubben dissekerer i dag tallene fra blandt andre Ørsted, Jyske Bank, Ambu, Pandora og Demant. Og så sætter vi stort fokus på de friske tal - og den dertilhørende nedjustering - fra det helt store danske aktieflagskib Novo Nordisk. Det gør vi sammen med vores faste porteføljeforvalter Michael Friis Jørgensen, der også er aktiechef i HC Andersen Capital, og adm. direktør i Global Health Invest, Claus Johansen, der står bag investeringsforeningen af samme navn. Har du spørgsmål til panelet så send dem afsted på 42 42 03 21 - du skal bare huske at starte din SMS med MIO. Vært: Adam Geil See omnystudio.com/listener for privacy information.

Good bosses are rare. They don't have to be. The skills of management can be learned.The Economist's management columnist, Andrew Palmer, is here to help. The second season of Boss Class features leaders at some of the world's best performing companies, from Levi's to Novo Nordisk to Google. New episodes are out weekly starting May 12th. To listen to the full series, subscribe to Economist Podcasts+. https://subscribenow.economist.com/podcasts-plusIf you're already a subscriber to The Economist, you have full access to all our shows as part of your subscription. For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account. Hosted on Acast. See acast.com/privacy for more information.

Another key Fed decision on deck, as the recent stock market bounce loses steam. What to expect from Fed Chair Jerome Powell, and what it will mean for the market's next move. Plus Earnings season in full swing, and Wegovy-maker Novo Nordisk is ready to report. Why one top healthcare analyst is eyeing potential tariff risks and political overhang as a headwind for the whole weight loss drug space.Fast Money Disclaimer

Good bosses are rare. They don't have to be. The skills of management can be learned.The Economist's management columnist, Andrew Palmer, is here to help. The second season of Boss Class features leaders at some of the world's best performing companies, from Levi's to Novo Nordisk to Google. New episodes are out weekly starting May 12th. To listen to the full series, subscribe to Economist Podcasts+. https://subscribenow.economist.com/podcasts-plusIf you're already a subscriber to The Economist, you have full access to all our shows as part of your subscription. For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account. Hosted on Acast. See acast.com/privacy for more information.

Good bosses are rare. They don't have to be. The skills of management can be learned.The Economist's management columnist, Andrew Palmer, is here to help. The second season of Boss Class features leaders at some of the world's best performing companies, from Levi's to Novo Nordisk to Google. New episodes are out weekly starting May 12th. To listen to the full series, subscribe to Economist Podcasts+. https://subscribenow.economist.com/podcasts-plusIf you're already a subscriber to The Economist, you have full access to all our shows as part of your subscription. For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account.

Guy Adami and Dan Nathan preview the upcoming Federal Reserve meetings, and the lingering effects of trade tensions with China. They highlight key economic indicators, such as the strength of the U.S. dollar, crude oil prices, and job numbers. The discussion also covers significant earnings reports for the week, including Apple, Palantir, Disney, Uber, and Novo Nordisk. The episode also touches on Warren Buffet's increasing cash reserves and broader market sentiment amidst geopolitical uncertainties. Timecodes 0:00 - SPX Key Levels 5:30 - Buffet's Cash & Risk 12:30 - Oil Impact 16:15 - AAPL & Indicators 21:00 - Sentiment 27:30 - Earnings To Watch —FOLLOW USYouTube: @RiskReversalMediaInstagram: @riskreversalmediaTwitter: @RiskReversalLinkedIn: RiskReversal Media

Good bosses are rare. They don't have to be. The skills of management can be learned.The Economist's management columnist, Andrew Palmer, is here to help. The second season of Boss Class features leaders at some of the world's best performing companies, from Levi's to Novo Nordisk to Google. New episodes are out weekly starting May 12th. To listen to the full series, subscribe to Economist Podcasts+. https://subscribenow.economist.com/podcasts-plusIf you're already a subscriber to The Economist, you have full access to all our shows as part of your subscription. For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account. Hosted on Acast. See acast.com/privacy for more information.

Good bosses are rare. They don't have to be. The skills of management can be learned.The Economist's management columnist, Andrew Palmer, is here to help. The second season of Boss Class features leaders at some of the world's best performing companies, from Levi's to Novo Nordisk to Google. New episodes are out weekly starting May 12th. To listen to the full series, subscribe to Economist Podcasts+. https://subscribenow.economist.com/podcasts-plusIf you're already a subscriber to The Economist, you have full access to all our shows as part of your subscription. For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account.

The United States Supreme Court rules against hospitals in an ongoing case about disproportionate share hospital payments. Aetna announces it will leave the healthcare exchanges. And, Novo Nordisk is partnering with telehealth companies to expand access to its GLP-1 drugs. Those stories and more coming up on today's episode of the Gist Healthcare Podcast. Hosted on Acast. See acast.com/privacy for more information.

Good bosses are rare. They don't have to be. The skills of management can be learned.The Economist's management columnist, Andrew Palmer, is here to help. The second season of Boss Class features leaders at some of the world's best performing companies, from Levi's to Novo Nordisk to Google. New episodes are out weekly starting May 12th. To listen to the full series, subscribe to Economist Podcasts+. https://subscribenow.economist.com/podcasts-plusIf you're already a subscriber to The Economist, you have full access to all our shows as part of your subscription. For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account. Hosted on Acast. See acast.com/privacy for more information.

Good bosses are rare. They don't have to be. The skills of management can be learned.The Economist's management columnist, Andrew Palmer, is here to help. The second season of Boss Class features leaders at some of the world's best performing companies, from Levi's to Novo Nordisk to Google. New episodes are out weekly starting May 12th. To listen to the full series, subscribe to Economist Podcasts+. https://subscribenow.economist.com/podcasts-plusIf you're already a subscriber to The Economist, you have full access to all our shows as part of your subscription. For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account.

Good bosses are rare. They don't have to be. The skills of management can be learned.The Economist's management columnist, Andrew Palmer, is here to help. The second season of Boss Class features leaders at some of the world's best performing companies, from Levi's to Novo Nordisk to Google. New episodes are out weekly starting May 12th. To listen to the full series, subscribe to Economist Podcasts+. https://subscribenow.economist.com/podcasts-plusIf you're already a subscriber to The Economist, you have full access to all our shows as part of your subscription. For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account. Hosted on Acast. See acast.com/privacy for more information.

Good bosses are rare. They don't have to be. The skills of management can be learned.The Economist's management columnist, Andrew Palmer, is here to help. The second season of Boss Class features leaders at some of the world's best performing companies, from Levi's to Novo Nordisk to Google. New episodes are out weekly starting May 12th. To listen to the full series, subscribe to Economist Podcasts+. https://subscribenow.economist.com/podcasts-plusIf you're already a subscriber to The Economist, you have full access to all our shows as part of your subscription. For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account.

Wegovy is on its way to Hims & Hers, Ro and LifeMD. In a landmark deal, after pulling the rug under these pharmacies for manufacturing dupes, Novo Nordisk is now pushing Wegovy through them. So, is this a good decision? Plus: Amazon enters the space race and Duolingo makes an AI pledge. Join our hosts Jon Weigell and Rob Litterst as they take you through our most interesting stories of the day. Get our Side Hustle Ideas Database: https://clickhubspot.com/thds Join The Hustle and the best and brightest Owners, Operations and Outliers (with $100 bucks off for community) at the OOO summit here: http://ooo.live/ (PROMOCODE: THEHUSTLE). Please add this under the side hustle database link. Follow us on social media: TikTok: https://www.tiktok.com/@thehustle.co Instagram: https://www.instagram.com/thehustledaily/ Thank You For Listening to The Hustle Daily Show. Don't forget to hit Subscribe or Follow us on Apple Podcasts so you never miss an episode! If you want this news delivered to your inbox, join millions of others and sign up for The Hustle Daily newsletter, here: https://thehustle.co/email/  Plus! Your engagement matters to us. If you are a fan of the show, be sure to leave us a 5-Star Review on Apple Podcasts https://podcasts.apple.com/us/podcast/the-hustle-daily-show/id1606449047 (and share your favorite episodes with your friends, clients, and colleagues).

Good bosses are rare. They don't have to be. The skills of management can be learned.The Economist's management columnist, Andrew Palmer, is here to help. The second season of Boss Class features leaders at some of the world's best performing companies, from Levi's to Novo Nordisk to Google. New episodes are out weekly starting May 12th. To listen to the full series, subscribe to Economist Podcasts+. https://subscribenow.economist.com/podcasts-plusIf you're already a subscriber to The Economist, you have full access to all our shows as part of your subscription. For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account. Hosted on Acast. See acast.com/privacy for more information.

Good bosses are rare. They don't have to be. The skills of management can be learned.The Economist's management columnist, Andrew Palmer, is here to help. The second season of Boss Class features leaders at some of the world's best performing companies, from Levi's to Novo Nordisk to Google. New episodes are out weekly starting May 12th. To listen to the full series, subscribe to Economist Podcasts+.https://subscribenow.economist.com/podcasts-plusIf you're already a subscriber to The Economist, you have full access to all our shows as part of your subscription. For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account. Hosted on Acast. See acast.com/privacy for more information.